Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2018-08-12 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于收到控股股东自愿性追加业绩承诺的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding a voluntary additional performance commitment by its controlling shareholder related to an acquisition transaction. It includes details about the transaction, performance targets, and commitments to protect shareholder interests. The document is short (924 characters) and does not contain financial statements or detailed financial data. It is an announcement about a transaction and related commitments rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including acquisition-related announcements.
2018-08-12 Chinese
关于对深圳证券交易所问询函回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from 康芝药业股份有限公司 responding to an inquiry letter from the Shenzhen Stock Exchange. It discusses the company's acquisition of 中山爱护, including business rationale, financial evaluations, audit opinions, and shareholder equity pledges. The content includes extensive financial data, audit references, and management explanations related to the acquisition and its impact on the company. It is not a full annual or quarterly report but a regulatory response to an exchange inquiry, containing detailed explanations and financial data supporting the acquisition and related risks. The document is not a simple announcement of a report but a substantive regulatory filing addressing specific questions from the exchange. Therefore, it fits best under Regulatory Filings (RNS).
2018-08-10 Chinese
拟收购股权所涉及的中山爱护日用品有限公司股东全部权益价值资产评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an "资产评估报告" (Asset Valuation Report) related to 康芝药业股份有限公司's proposed acquisition of equity in 中山爱护日用品有限公司. It is issued by 上海众华资产评估有限公司 and dated July 13, 2018. The report includes detailed valuation methods, financial data, ownership structure, and audit opinions. It is a comprehensive asset valuation report used to assess the market value of the target company's equity for acquisition purposes. This type of document is a standalone asset valuation or appraisal report, which fits the category of Audit Report / Information (AR) rather than a full Annual Report or other categories. It is not an announcement or a brief summary but a detailed valuation report with substantive financial data and analysis. Q1 2018
2018-08-10 Chinese
关于召开2018年第二次临时股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2018 second extraordinary general meeting of shareholders for 康芝药业股份有限公司. It includes information about the meeting date, voting procedures (both in-person and online), agenda items to be discussed and voted on, registration details, and proxy forms. The content focuses on informing shareholders about the meeting logistics and proposals to be voted on, rather than presenting financial results, audit opinions, or management discussions. There is no indication that this is a transcript, financial report, or legal proceeding update. The document is not a report itself but an announcement and notice about the shareholder meeting and voting process. Therefore, it fits best into the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2018-08-08 Chinese
监事会关于公司2018年股票期权激励计划激励对象名单的审核意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of Kangzhi Pharmaceutical Co., Ltd. regarding the review and public disclosure of the list of incentive recipients under the company's 2018 stock option incentive plan. It includes details about the public notice period, the verification process of the incentive recipients, and the supervisory board's opinion confirming the legality and validity of the incentive recipients. The document does not contain financial statements, earnings data, or detailed financial analysis. It is not a full report but rather an official announcement related to corporate governance and compliance with stock option incentive regulations. This fits best under Regulatory Filings (RNS) as it is a compliance-related announcement that does not fit other specific categories such as management changes, earnings, or capital updates.
2018-08-08 Chinese
关于签署募集资金多方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a multi-party supervision agreement for raised funds related to a specific investment project. It details the parties involved, the account setup, supervision responsibilities, and procedural rules. There are no financial statements, earnings data, or detailed financial analysis. The document is relatively short (2359 characters) and serves as a formal announcement of an agreement related to capital management and fundraising oversight. This fits the category of Capital/Financing Update (CAP), as it concerns the management and supervision of raised capital funds.
2018-07-31 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.